中心审核与MRI质量对前列腺癌诊断及活检决策的影响
本研究回顾性纳入154例在外院行前列腺MRI后转诊至三级癌症中心拟行活检的患者,所有MRI均经设盲专家中心审核并重新评估PI-RADS v2.1与PI-QUAL v2评分。结果显示中心审核显著提高了csPCa检测的AUC及活检决策准确性,获益主要见于图像质量可接受的病例。
要点
- 外院前列腺MRI报告可经专家中心审核显著改善诊断性能与活检建议。
- PI-QUAL v2=1的图像即使经中心审核其诊断可靠性仍差。
- 对PSA<10 ng/mL且初次不建议活检者,中心审核可上调部分病例并检出csPCa。
核心结论
- 专家中心审核在转诊患者中有改善前列腺MRI解读和活检决策的潜力。
- MRI图像质量仍是诊断可靠性的关键决定因素,PI-QUAL v2=1时中心审核无显著获益。
研究设计与样本
- 所有MRI均经设盲专家中心审核并重新评估PI-RADS v2.1及PI-QUAL v2评分。
关键影像表现/征象
- 以PI-RADS≥3为阈值,中心审核的诊断准确性、敏感度和特异度均优于外院初次评估。
- 可接受图像质量(PI-QUAL v2>1)的检查经中心审核后活检决策准确性由0.768升至0.870。
- 图像质量不充分(PI-QUAL v2=1)的检查经中心审核后活检决策准确性无显著改善。
诊断标准与关键数值
- 以PI-RADS≥3为阳性阈值,中心审核的诊断准确性、敏感度和特异度均提高,均P<0.05。
- PSA<10 ng/mL患者中,中心审核将36.4%(4/11)初次不建议活检者升级为建议活检,其中75.0%最终确诊为csPCa。
临床应用与阅片要点
- 对外院前列腺MRI建议常规进行图像质量评估,PI-QUAL v2=1时应谨慎解读并考虑重复检查。
- 转诊路径中加入专家中心审核有助于改善PI-RADS解读并优化活检决策。
- PSA<10 ng/mL的转诊患者可从中心审核中获得更精准的活检与豁免决策。
局限性
- 本研究为单中心回顾性设计。
- 本研究仅纳入转诊至单一三级癌症中心的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the impact of central review on prostate MRI interpretation, clinically significant prostate cancer (csPCa) detection, and biopsy decision-making in referred patients, and to investigate the influence of MRI image quality on diagnostic performance.
METHODS: This retrospective study included consecutive patients referred to a tertiary cancer center for biopsy after undergoing prostate MRI at external hospitals between December 2024 and November 2025. All MRI examinations underwent blinded expert central review with reassessment of Prostate Imaging Reporting and Data System (PI-RADS) v2.1 and Prostate Imaging Quality (PI-QUAL) v2 scores. Diagnostic performance and biopsy recommendations based on local assessments and central review were compared using area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.
RESULTS: A total of 154 patients were included, of whom 76.0% (117/154) had csPCa. Compared with local assessments, central review significantly improved diagnostic performance for csPCa detection (AUC: 0.653 [0.558-0.747] vs 0.860 [0.785-0.936], P < 0.001). Using PI-RADS ≥ 3 as the threshold, central review improved diagnostic accuracy, sensitivity, and specificity (all P < 0.05). Biopsy decision accuracy also improved from 0.779 [0.705-0.842] to 0.857 [0.792-0.908] (P < 0.05), with the benefit primarily observed in examinations with acceptable image quality (PI-QUAL v2 > 1: 0.768 [0.651-0.861] vs 0.870 [0.767-0.939], P < 0.05), whereas no significant improvement was observed in PI-QUAL v2 = 1 examinations. In patients with prostate-specific antigen < 10 ng/mL, central review escalated 36.4% (4/11) of initially non-biopsy-recommended patients to biopsy, with 75.0% confirmed as csPCa, while avoiding 18.0% (11/61) of initially recommended biopsies; the only missed csPCa case (9.1% [1/11]) occurred in a PI-QUAL v2 = 1 examination.
CONCLUSION: Expert central review showed potential in improving prostate MRI interpretation and biopsy decision-making in referred patients. However, MRI image quality remains a critical determinant of diagnostic reliability, supporting routine implementation of image quality assessment and expert consultation in referral pathways.
引用
- Zheng, Liu, Wu, et al. Impact of central review and MRI image quality on prostate cancer diagnosis and biopsy decision-making in referred patients. Abdom Radiol (NY). 2026. PMID: 42517901. doi:10.1007/s00261-026-05697-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。